

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 25-1-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 03-11-2007 TO BE PUBLISHED ON 26-1-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1259/2007	<u>30-10-2007</u> AstraZeneca AB. Sweden. Priority (03-11-2006 USA)	“Chemical compounds”
1260/2007	Zakiuddin Ahmed. PCSIR. Karachi.	“A process for the production of vitacoal compound from lakhra lignite coal”
1261/2007	Zakiuddin Ahmed. PCSIR. Karachi.	“A process for the production of alternate fuel oil (named as FR-AFO-II) from waste coke breeze (by product of coke oven battery)”
1262/2007	Zakiuddin Ahmed. PCSIR. Karachi.	“A process for the production of iron nitro humate (named as coal iron) for iron deficient crops from Pakistan Coal”
1263/2007	Zakiuddin Ahmed. PCSIR. Karachi.	“A process for the production of potassium nitro humate (named as coal potash) for potassium deficient crops from Pakistan Coal”
1264/2007	Sanofi-Aventis. Germany. Priority (02-11-2006 DE)	“Novel diphenylazetidione substituted by piperazine-1-sulfonic acid and having improved pharmacological properties”
1265/2007	Dr. M. Bilal Khan. HQ. Nust (R&D Dte) Islamabad-Pakistan.	“Novel method of tackling erosive burning in high L/D solid rocket motor”
1266/2007	<u>31-10-2007</u> Targacept, Inc. USA. Priority (02-11-2006 USA)	“Sub-type selective amides of diazabicycloalkanes”
1267/2007	Wyeth. USA. Priority (31-10-2006 USA)	“Formulations of phospholipase enzyme inhibitors”
1268/2007	Wyeth. USA. Priority (31-10-2006 USA)	“Semi-solid formulations of phospholipase enzyme inhibitors”
1269/2007	Wyeth. USA. Priority (31-10-2006 USA)	“Liquid formulations of phospholipase enzyme inhibitors”

1270/2007	Wyeth. USA. Priority (31-10-2006 USA)	“Liquid formulation of phospholipase enzyme inhibitors”
<u>01-11-2007</u>		
1271/2007	Telefonaktiebolaget LM Ericsson (Publ) Sweden. Priority (03-11-2006 USA)	“Method of conditionally routing a call made to a fixed telephone number”
1272/2007	Trondheim, Norway. Priority (01-11-2006 Norway)	“Method for liquefaction of gas”
1273/2007	F. L. Smith A/S. Denmark. Priority (29-11-2006 Denmark)	“Burner”
1274/2007	F. L. Smith A/S. Denmark. Priority (29-11-2006 Denmark)	“Burner”
<u>02-11-2007</u>		
1275/2007	Urea Casale S.A. Switzerland. Priority (04-11-2006 EP)	“Process for urea production and related plant”
1276/2007	Urea Casale S.A. Switzerland. Priority (04-11-2006 EP)	“Integrated process for urea and melamine production”
1277/2007	Invista Technologies S.A.R.L. Switzerland. Priority (03-11-2006 GB)	“Oxidation reaction for producing aromatic carboxylic acids”
1278/2007	Invista Technologies S.A.R.L. Switzerland. Priority (03-11-2006 GB)	“Oxidation reaction for producing aromatic carboxylic acids”
1279/2007	Plasco Energy Group Inc. Canada. Priority (02-11-2006 USA)	“A low temperature gasification facility with a horizontally oriented gasifier”
1280/2007	Plasco Energy Group Inc. Canada. Priority (02-11-2006 USA)	“A control system for the conversion of a carbonaceous feedstock into gas”
<u>03-11-2007</u>		
1281/2007	Glenmark Pharmaceuticals S.A. Switzerland. Priority (03-11-2006 India)	“Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation”
1282/2007	Muhammad Yasin Khan Chichawatni-Pakistan	“Soft water harvesting plant”

1283/2007

1. Dr. Tariq Masud.
2. Malik Adil Nawaaz
3. Shehla sammi.
Rawalpindi-Pakistan.

“Mozzarella cheese preparation using paneer
booti (Withania coagulans)”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


465/2001 Merck & Co. Inc.,

“5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-
[2,3']bipyridinyl in pure crystalline form”

(C30B, 29/54)

139322

This invention encompasses the form V polymorph of
compound A of structural formula



Compound A

Which is useful in the treatment of cyclooxygenase -2 mediated diseases. The invention encompasses certain pharmaceutical compositions for treatment of cyclooxygenase -2- mediated disease comprising the form V polymorph of compound A. The invention also encompasses of process synthesizing the form V polymorph of compound A.


433/2003 Bristol-Myers Squibb
Company,
USA

“Proline compound”

(CO7D, 207/12)

139323

Hepatitis C virus inhibitor are disclose having the general formula:



Where in R1, R2, R3, R4, B, Y and X are described in the descriptions compositions comprising the compounds and methods for using the compounds 2 inhibit HCV are also disclosed

722/2003 F. Hoffmann-La Roche
AG,
Switzerland

“A pharmaceutical composition containing
biphosphonate as active substance”

(A61K, 31/66)

139324

This invention relates to pharmaceutical composition for oral application, consisting of a high dose of bisphosphonates or physiologically safe salt thereof as an active substance, which may be used for treating bone diseases and some disturbance of calcium metabolism.